# Qlife Lab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qlife-lab

- Industry: Medical Devices & Equipment
- Headquarters: Nanjing, China
- Website: www.qlife-lab.com
- Latest round: Series B (Oct 22, 2021)
- Investors on record: 7

## About

Based in Shenzhen, China and established in 2016, Qlife Lab is a biomedical company which develops high throughput mass spectrometry technology, offering metabolomics/proteomics-based assays and laboratory diagnostic tests to enable early prevention and intervention of a variety of diseases. The CEO (Chief Executive Officer) and founder Dr. Xiaoliang Cheng served in LBNL(Lawrence Berkeley National Laboratory) and has nearly 20 years of experience in the development of innovative mass spectrometry technology and clinical applications. In 2020, the company launched the first clinical mass spectrometer Qlife Lab 9000.

The company's provides third-party medical inspection services, in vitro diagnostic reagent products and supporting technical services for customers. The company's provides mass spectrometry routine inspection include hypertension markers, vitamins, steroid hormones, metabolites profiling and theraputic drug monitoring, and mass spectrometry precision disease inspection include cardiovascular disease risk screening, early tumor screening, early diabetes screening and pre-screening test for gestational diabetes. Besides, the company launched screening and diagnostic products for cardiovascular disease, tumor, neuropathy, metabolic disease, and neonatal genetic disease.

The company plan to use the series B funding for research and development of clinical mass spectrometry equipment and related diagnostic reagents, and expand infrastructure such as workshops and laboratories.

## Funding rounds

- Series B, Oct 22, 2021 — Cowin Capital, Centurium Cap, Beichen Capital, Sihua Investment
- Series A, Feb 21, 2019 — StarVC, Yangtze River Capital
- Series A, Jun 15, 2018 — IDG Capital, StarVC
- Angel, Jun 15, 2017 — IDG Capital

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Angel, Series A
- StarVC (https://capitalatlas.ai/funds/starvc) — Series A
- Yangtze River Capital (https://capitalatlas.ai/funds/yangtze-river-capital) — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- Centurium Cap — Series B
- Beichen Capital (https://capitalatlas.ai/funds/beichen-capital) — Series B
- Sihua Investment (https://capitalatlas.ai/funds/sihua-investment) — Series B